Background
Hepatic steatosis (HS) is common in persons with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections, but the independent contributions of HCV and HIV to HS is unclear.
Methods
Magnetic resonance imaging and spectroscopy were used to measure visceral adipose tissue (VAT) and liver fat fraction (LFF) [total lipids/(total lipids+water)] in 356 adults: 57 HCV-monoinfected, 70 HIV/HCV-coinfected, 122 HIV-monoinfected, and 107 HIV/HCV-uninfected. Genotype 3 HCV-infected participants were excluded due to the genotype's reported steatogenic effects. For prevalence estimates, HS was defined as LFF≥0.05. We estimated the association of HIV and HCV status with LFF using multivariable linear regression, adjusting for demographic, lifestyle, and metabolic factors including the homeostasis model assessment estimate of insulin resistance (HOMA-IR) and liver fibrosis defined using the AST-to-platelet ratio index (APRI).
Results
The prevalence of HS was highest in the uninfected(33%) and HIV-monoinfected(28%), followed by the HCV-monoinfected(19%) and HIV/HCV-coinfected(11%)(p=0.003 across groups). Compared to uninfected participants, after adjusting for demographic, lifestyle, and metabolic factors, HIV monoinfection, HCV monoinfection and HIV/HCV coinfection were associated with 19%(95%CI:-39%,6%), 38%(95%CI:-55%,-12%) and 42%(95%CI:-59%,-18%) lower LFF, respectively. HCV monoinfection and HIV/HCV coinfection remained strongly associated with lower LFF after further adjusting for APRI, and results were unchanged after excluding subjects with suspected cirrhosis. Among the entire cohort, Hispanic ethnicity, male sex, VAT, and HOMA-IR were independently associated with greater LFF.
Conclusions
Contrary to expectations, HIV/HCV-coinfected and HCV-monoinfected adults had significantly less liver fat than uninfected adults, even after adjusting for demographic, lifestyle, metabolic factors, and hepatic fibrosis. Our findings suggest that non-genotype 3 HCV infection may be protective against HS. The mechanisms by which this occurs and impact of HCV treatment on HS need investigation.